Potential treatment for patients with acute myeloid leukaemia
16 March 2023
Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, has been granted Orphan Drug Designation (ODD) by the FDA for EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia (AML). In February 2023, the FDA […]